# The insider's perspective: The intracellular complosome and immune cell dynamics in cancer

**Authors:** Alexandra Bennion, Joanne Lysaght, Niamh Lynam‐Lennon

PMC · DOI: 10.1002/ctm2.70628 · Clinical and Translational Medicine · 2026-02-20

## TL;DR

This paper explores how intracellular complement (complosome) influences cancer immunity, affecting immune cell function and tumor growth.

## Contribution

The paper introduces the complosome as a novel target for cancer immunotherapy by detailing its role in immune cell dynamics.

## Key findings

- Complosome activity rewires T-cell metabolism and promotes pro-tumor immune cell function.
- Blocking the complosome reveals a new therapeutic target in cancer.
- C3/C5-driven complosome signals influence T-cell activation and tumor immunity.

## Abstract

Complement is increasingly recognised as a driver and modulator of antitumour immunity, with context‐dependent effects across T cells, myeloid subsets, stromal elements and tumour cells. Although best known for pathogen clearance and membrane attack complex (MAC) formation, complement also acts intracellularly via the ‘complosome’ to regulate cellular homeostasis and gene expression. Complosome activity may dampen antitumour responses by rewiring single‐cell metabolism and transcription, altering nutrient flux and fostering an immunosuppressive microenvironment. Here, we synthesise advances in intracellular and extracellular complement, with emphasis on complement component 3 (C3) and receptors (C3aR1, C5aR1/CD88, C5aR2/C5L2), highlighting how these pathways shape T‐cell metabolism, exhaustion programmes and inflammatory tone within tumours. Evidence indicates that tonic C3/C5 signalling restrains cytotoxicity via C5aR1‐driven myeloid recruitment and cytokine cascades, while complosome signalling tunes T‐cell activation thresholds and bioenergetics. We outline considerations for selectively modulating intracellular versus extracellular complement, propose cell‐type‐resolved biomarker strategies and identify opportunities for complosome‐directed therapies in cancer, integrating roles across T cells, macrophages, B cells, neutrophils, NK cells, regulatory T cells, dendritic cells, myeloid‐derived suppressor cells and cancer‐associated fibroblasts.

Intracellular complement (complosome) shapes the tumor immune microenvironment.Complosome's role in cancer is underrecognized yet central to tumor immunity.C3/C5‐driven complosome signals rewire T cell activation, fate, and metabolism.
Complosome activity can promote pro‐tumor immune cell function.Blocking the complosome, alone or with checkpoint inhibitors, unveils a new tumor target.

Intracellular complement (complosome) shapes the tumor immune microenvironment.

Complosome's role in cancer is underrecognized yet central to tumor immunity.

C3/C5‐driven complosome signals rewire T cell activation, fate, and metabolism.
Complosome activity can promote pro‐tumor immune cell function.

Blocking the complosome, alone or with checkpoint inhibitors, unveils a new tumor target.

Intracellular complement (complosome) shapes the tumour immune microenvironment.

Complosome's role in cancer is underrecognised yet central to tumour immunity.

C3/C5‐driven complosome signals rewire T‐cell activation, fate and metabolism.

Complosome activity can promote pro‐tumour immune cell function.

Blocking the complosome, alone or with checkpoint inhibitors, unveils a new tumour target.

## Linked entities

- **Proteins:** C3 (complement C3), C3AR1 (complement C3a receptor 1)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, Ctsl (cathepsin L) [NCBI Gene 13039] {aka 1190035F06Rik, CatL, Ctsl1, MEP, fs, nkt}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, IL21 (interleukin 21) [NCBI Gene 59067] {aka CVID11, IL-21, Za11}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, Cd46 (CD46 antigen, complement regulatory protein) [NCBI Gene 17221] {aka Mcp}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, C3AR1 (complement C3a receptor 1) [NCBI Gene 719] {aka AZ3B, C3AR, HNFAG09}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Kctd5 (potassium channel tetramerisation domain containing 5) [NCBI Gene 69259] {aka 2610030N08Rik, mKIAA0176}, Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, JAG1 (jagged canonical Notch ligand 1) [NCBI Gene 182] {aka AGS, AGS1, AHD, AWS, CD339, CMT2HH}, CD46 (CD46 molecule) [NCBI Gene 4179] {aka AHUS2, MCP, MIC10, TLX, TRA2.10}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, C3ar1 (complement component 3a receptor 1) [NCBI Gene 12267] {aka AZ3B, C3AR, HNFAG09}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Itgb2 (integrin beta 2) [NCBI Gene 16414] {aka 2E6, Cd18, LAD, LCAMB, Lfa1, MF17}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, C4A (complement C4A (Chido/Rodgers blood group)) [NCBI Gene 720] {aka C4, C4A2, C4A3, C4A4, C4A6, C4AD}, LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 1) [NCBI Gene 55004] {aka C11orf59, PDRO, Ragulator1, p18, p27RF-Rho}, C1S (complement C1s) [NCBI Gene 716] {aka EDSPD2}, PIWIL1 (piwi like RNA-mediated gene silencing 1) [NCBI Gene 9271] {aka CT80.1, HIWI, MIWI, PIWI}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, Cul3 (cullin 3) [NCBI Gene 26554] {aka KIAA0617}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Nos1 (nitric oxide synthase 1, neuronal) [NCBI Gene 18125] {aka 2310005C01Rik, N-NOS, NC-NOS, NO, NOS, NOS-I}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) [NCBI Gene 20525] {aka GT1, Glut-1, Glut1, M100200, Rgsc200}, Ctss (cathepsin S) [NCBI Gene 13040] {aka Cats}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, H1-0 (H1.0 linker histone) [NCBI Gene 3005] {aka H1.0, H10, H1F0, H1FV}, Ccnd1 (cyclin D1) [NCBI Gene 12443] {aka CycD1, Cyl-1, PRAD1, bcl-1, cD1}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, C5ar1 (complement component 5a receptor 1) [NCBI Gene 12273] {aka C5aR, C5r1, Cd88, D7Msu1}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, CTSL (cathepsin L) [NCBI Gene 1514] {aka CATL, CTSL1, MEP}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** cSCC (MESH:D002294), glioblastoma (MESH:D005909), NSCLC (MESH:D002289), SLE (MESH:D008180), CELLS (MESH:D002292), C3 (MESH:C565169), hepatocellular carcinoma (MESH:D006528), gastrointestinal cancers (MESH:D005770), SYSTEM (MESH:D015619), oncogenic (MESH:D000074723), carcinogenesis (MESH:D063646), ovarian cancer (MESH:D010051), NET (MESH:C536657), lymphoma (MESH:D008223), bacterial (MESH:D001424), autoimmunity (MESH:D001327), gastric cancer (MESH:D013274), lymph node metastasis (MESH:D008207), breast cancer (MESH:D001943), TNBC (MESH:D064726), cytotoxicity (MESH:D064420), acute pancreatitis (MESH:D010195), rectal cancer (MESH:D012004), MDSCs (OMIM:601308), infection (MESH:D007239), lung cancer (MESH:D008175), T (MESH:D001260), OAC (MESH:D000230), Cancer (MESH:D009369), tumorigenic (MESH:D002471), myeloid (MESH:D007951), influenza (MESH:D007251), neutrophil (MESH:C564275), breast (MESH:D061325), cervical cancer (MESH:D002583), CD46 deficiency (MESH:D007153), IMMUNE CELL DYNAMICS (MESH:D000092242), CRC (MESH:D015179), pancreatic cancer (MESH:D010190), injury (MESH:D014947), T-cell dysfunction (MESH:C536780), chronic inflammation (MESH:D007249), pancreatic, gastric and breast cancer (MESH:C537262), melanoma (MESH:D008545), ischaemia-reperfusion injury (MESH:D015427), metastases (MESH:D009362)
- **Chemicals:** glucose (MESH:D005947), PMX205 (MESH:C504156), galactose (MESH:D005690), SB290157 (MESH:C431907), ROS (MESH:D017382), essential amino acids (MESH:D000601), Ag (MESH:D012834), PMX53 (MESH:C438957), ATP (MESH:D000255), carbohydrate (MESH:D002241), paclitaxel (MESH:D017239), rituximab (MESH:D000069283), amino acid (MESH:D000596), C3 (-), CCX168 (MESH:C000620232), FOLFOX (MESH:C410216)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Listeria monocytogenes (species) [taxon 1639]
- **Cell lines:** 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922784/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922784/full.md

## References

185 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922784/full.md

---
Source: https://tomesphere.com/paper/PMC12922784